Gts Securities LLC Crispr Therapeutics Ag Call Options Transaction History

Gts Securities LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $931,294 - $1.24 Million	-18,200 Reduced 27.91%	47,000 $2.54 Million
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $552,097 - $810,992	9,100 Added 16.22%	65,200 $4.44 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $293,512 - $548,568	7,600 Added 15.67%	56,100 $3.51 Million
Q3 2023 Nov 15, 2023	BUY	$45.39 - $59.0 $2.2 Million - $2.86 Million	48,500 New	48,500 $2.2 Million

499

56.8M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.